Kestrel Therapeutics Receives FDA Fast Track Designation for KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, in the treatment of KRAS-Mutant Advanced Solid Tumors

RegulatoryKST-6051Positive

AI Analysis

Summary

Kestrel Therapeutics received FDA Fast Track designation for KST-6051, a potential best-in-class pan-KRAS inhibitor, for treating advanced or metastatic solid tumors with KRAS mutations. The Fast Track status accelerates the development and review process for this next-generation small-molecule therapeutic candidate.

Outcome Details

FDA Fast Track designation granted

Importance:7/10

Sentiment:

0.80

FDA Fast TrackKRAS inhibitorpan-KRASsmall-moleculeoralsolid tumorsregulatory designation

Related Companies

$GBIO $INTI $SLDB

Read the original article

Published by GlobeNewswire Clinical Studies on September 15, 2026 12:00 PM

Read Original